These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Hypotensive effect and characteristics of the effect on the central hemodynamics of the delayed-action form of diltiazem (Dilren) in patients with hypertension].
    Author: Pshenitsin AI, Glotov MN, Mazur NA.
    Journal: Ter Arkh; 1993; 65(9):47-50. PubMed ID: 8303596.
    Abstract:
    Calcium antagonist dilren in a short course was given to 11 hypertensive subjects (AH stage II). A clinical response in the majority of the patients was associated with a decline in systolic, mean arterial and resting diastolic pressure (by 8.1, 7.8 and 11.5%, respectively). In orthostasis and under isometric loading dynamic values of arterial pressure tended to lowering, especially diastolic (by 6.7 and 8.3%, respectively). Reduced pressure resulted from a significant reduction in the total peripheral resistance (by 19.8% at rest, in orthostasis by 10%, in isometric load by 26.1%). Minute blood volume increased because of a rise in stroke output. Dilren is recommended in a standard dose 300 mg/day in mild hypertension and in an individual dose 600 mg/day in moderate disease.
    [Abstract] [Full Text] [Related] [New Search]